Aclarion provides corporate update following Q1 strategic initiatives

Aclarion (ACON) provided a corporate update on its strengthened positioning following the execution of strategic initiatives in Q1 2025. “Aclarion significantly improved its financial and Nasdaq compliance positioning throughout Q1 such that we are now very well positioned to execute on our strategic plan of driving Nociscan to standard of care,” said Jeff Thramann, MD, Executive Chairman of Aclarion. “The team is rapidly enrolling sites for the CLARITY trial, and we look forward to demonstrating that the use of Nociscan data improves surgical decision making and outcomes. We believe this will be a game changing catalyst for Aclarion and for how chronic low back pain is evaluated and treated.” Key Financial and Strategic Highlights: Over $20 million raised in Q1 with nearly $15 million in cash on hand; Clean cap table, Zero debt, No preferred outstanding, No near-term warrant overhang. Fully Nasdaq compliant, meeting both bid price and shareholder equity requirements; Clarity trial for Nociscan fully funded; Secured additional payer approvals in England; Expanded physician referral and commercial support for Nociscan in U.S.